Repurposing Ivermectin and ATRA as Potential Therapeutics for Glioblastoma Multiforme

Background Glioblastoma multiforme (GBM) is the most aggressive and lethal form of primary brain tumor, characterized by rapid growth and resistance to conventional therapies. Despite advances in treatment, most patients succumb to the disease within 15 months. Drug repurposing, which involves finding new uses for existing drugs, is a promising strategy to develop new GBM treatments faster and more cost-effectively.

Method We obtained single-cell RNA sequencing (scRNA-seq) data (GSE84465) from the National Institutes of Health (NIH) Gene Expression Omnibus (GEO) repository to compare gene expression in GBM neoplastic cells and non-neoplastic cells. We identified genes that were abnormally expressed in tumor cells and linked these genes to potential drug targets. To identify potential repurposed drugs for GBM, we leveraged the Chemical Entities of Biological Interest (ChEBI) database to assess the interaction of various compounds with the differentially expressed genes identified in the scRNA-seq analysis. We focused on compounds that could reverse the aberrant gene expression observed in GBM neoplastic cells.

Results Our analysis suggests that ivermectin and all-trans-retinoic acid (ATRA) could be repurposed as effective treatments for GBM. Ivermectin, typically used as an antiparasitic, demonstrated strong anti-tumor activity by downregulating 40 of the top 100 upregulated genes in GBM, indicating its potential to suppress tumor growth. ATRA, known for promoting cell differentiation, upregulated 60 genes typically downregulated in GBM neoplastic cells, showing its potential to correct transcriptional dysregulation and support tumor suppression. These findings underscore the promise of drug repurposing to target key pathways in GBM, offering new therapeutic options for this aggressive cancer.

Conclusions Our results provide compelling evidence that ivermectin and ATRA may be effective in treating GBM. The observed alterations in gene expression indicate the ability of these two agents to disrupt key genes and pathways crucial for tumor progression. Given the increasing interest in drug repurposing for cancer treatment, comprehensive preclinical and clinical investigations are warranted to assess fully the therapeutic efficacy of these compounds against this disease.